Patient Information Leaflet
Everolimus Ethypharm 2.5 mg Tablets
Read this leaflet carefully before you start taking this medicine, as it contains important information for you.
1. What is Everolimus Ethypharm and what is it used for
2. What you need to know before taking Everolimus Ethypharm
3. How to take Everolimus Ethypharm
4. Possible side effects
5. Storage of Everolimus Ethypharm
6. Contents of the pack and additional information
Everolimus Ethypharm is a cancer medication that contains the active ingredient everolimus. Everolimus reduces blood supply to the tumor and delays the growth and spread of cancer cells.
Everolimus Ethypharm is used to treat adult patients with:
Everolimus Ethypharm will only be prescribed to you by a doctor with experience in cancer treatment. Follow carefully all the instructions given by your doctor. These may be different from the general information contained in this leaflet. If you have any doubts about Everolimus Ethypharm or the reason why you have been prescribed this medicine, consult your doctor.
Do not takeEverolimus Ethypharm
If you think you may be allergic, consult your doctor.
Warnings and precautions
Consult your doctor before starting to takeEverolimus Ethypharm:
Everolimus may also:
Inform your doctor if you are scheduled to receive radiation therapy soon, or if you have received radiation therapy previously.
Inform your doctorif you experience these symptoms.
During treatment, you will have blood tests performed periodically.These tests will determine the number of blood cells (white blood cells, red blood cells, and platelets) to check if everolimus is having an undesirable effect on these cells.You will also have blood tests to monitor kidney function (creatinine level), liver function (transaminase level), and blood sugar and cholesterol levels.These tests are performed because these may be affected by everolimus treatment.
Children and adolescents
Everolimus Ethypharm should not be administered to children or adolescents (under 18 years old).
Other medicines andEverolimus Ethypharm
Everolimus Ethypharm may affect how other medicines work.If you are taking other medicines at the same time as Everolimus Ethypharm, your doctor may change the dose of Everolimus Ethypharm or the other medicines.
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medicine.
The following may increase the risk of side effects with everolimus:
used to treat fungal infections.
used to treat transplant rejection.
The following may reduce the effectiveness of everolimus:
You should avoid using these medicines during everolimus treatment.If you are taking any of them, your doctor may prescribe a different medicine, or may change your everolimus dose.
TakingEverolimus Ethypharmwith food and drinks
Do not take grapefruit or grapefruit juice while takingEverolimus Ethypharm. It may increase the amount ofEverolimus Ethypharmin the blood, possibly to a harmful level.
Pregnancy, breastfeeding, and fertility
Pregnancy
Everolimusmay cause harm to the fetus and is not recommended for use during pregnancy.Inform your doctor if you are pregnant or think you may be pregnant.Your doctor will discuss with you whether you should take this medicine during pregnancy.
Women who may become pregnant should use a highly effective contraceptive method during treatment and for 8 weeks after stopping treatment.If, despite these measures, you think you may be pregnant, consult your doctorbeforetaking moreof this medicine.
Breastfeeding
Everolimusmay cause harm to the breastfeeding baby.Do not breastfeed during treatment and for 2 weeks after the last dose ofeverolimus. Inform your doctor if you are breastfeeding.
Female fertility
In some patients treated witheverolimusamenorrhea (absence of menstrual periods) has been observed.
Everolimusmay affect female fertility.Inform your doctor if you want to have children.
Male fertility
Everolimusmay affect male fertility.Consult your doctor if you want to be a father.
Driving and operating machinery
If you feel abnormally tired (fatigue is a very common side effect), be extra careful when driving or operating machinery.
Everolimus Ethypharm contains lactose
This medicine contains lactose (milk sugar).If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medicine.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
The recommended dose is 10 mg, once a day. Your doctor will inform you about how many tablets of Everolimus Ethypharm you should take.
If you have liver problems, your doctor may start treatment with a lower dose of Everolimus Ethypharm (2.5; 5; or 7.5 mg per day).
If you experience some adverse effects while taking Everolimus Ethypharm (see section 4), your doctor may reduce the dose you take or interrupt treatment for a short period of time or permanently.
Take Everolimus Ethypharm once a day, more or less at the same time, always with food or always without food.
Swallow the tablets whole with a glass of water. The tablets should not be chewed or crushed.
If you take more Everolimus Ethypharm than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicological Information Service (Tel. 91 562 04 20) indicating the medication and the amount ingested.
If you forgot to take Everolimus Ethypharm
If you have forgotten a dose, take the next dose at the time it is due. Do not take a double dose to compensate for the missed doses.
If you interrupt treatment with Everolimus Ethypharm
Do not stop treatment with Everolimus Ethypharm unless your doctor tells you to.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
STOP treatment with everolimus and seek medical help immediately if you experience any of the following signs of an allergic reaction:
The serious side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
If you experience any of these side effects, report them to your doctor immediately as they may have fatal consequences.
Other possible side effects of everolimus include:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people))
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
If these adverse reactions worsen, report them to your doctor and/or pharmacist. Most side effects are mild to moderate and usually disappear if treatment is interrupted for a few days.
Reporting of adverse reactions
If you experience any type of adverse reaction, consult your doctor or pharmacist, even if it is a possible adverse reaction that does not appear in this prospectus. You can also report them directly through the Spanish System of Pharmacovigilance of Medicines for Human Use: www.notificaRAM.es. By reporting adverse reactions, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and in the blister pack. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Store in the original packaging to protect it from light.
Open the blister pack just before taking the tablets.
Do not use this medication if you observe that the packaging is damaged or shows signs of manipulation.
Medications should not be disposed of through drains or in the trash. Deposit the packaging and medications that you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications that you no longer need. By doing so, you will help protect the environment.
Composition of Everolimus Ethypharm
Each Everolimus Ethypharm tablet contains 2.5 mg of everolimus.
Appearance of the product and contents of the package
Everolimus Ethypharm 2.5 mg tablets are white to off-white, oblong-shaped tablets, 9.6 x 4.5 mm. It hasthe inscription"E" on one face and "2.5" on the other.
Everolimus Ethypharm 2.5 mg is available in packages containing 30 or 90 tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
Ethypharm
194 Bureaux de la Colline – Building D
92213 Saint-Cloud cedex
France
Responsible for manufacturing
Ethypharm
Chemin de la Poudrière
76120 Grand Quevilly
France
Ethypharm
Z.I. de Saint Arnoult
28170 Châteauneuf en Thymerais
France
For more information about this medication, please contact the local representative of the marketing authorization holder:
ALTAN PHARMACEUTICALS S.A.
C/Colquide, Nº 6, Portal 2, 1st floor, Office F. Edificio Prisma
Las Rozas (Madrid)
28230 Spain
This medication is authorized in the member states of the European Economic Area withthe following names:
Sweden: | Everolimus Ethypharm 2.5 mg, tabletter |
Austria: Germany: | Everolimus Ethypharm 2.5 mg, tabletten Everolimus Ethypharm 2.5 mg, tabletten |
Denmark: Italy: | Everolimus Ethypharm 2.5 mg, tabletter Everolimus Ethypharm |
Finland: Netherlands: Norway: Portugal: | Everolimus Ethypharm 2.5 mg, tabletti Everolimus Ethypharm 2.5 mg, tabletten Everolimus Ethypharm Everolímus Ethypharm 2.5 mg, tablets |
Spain: | Everolimus Ethypharm 2.5 mg, tablets EFG |
United Kingdom: | Everolimus Ethypharm 2.5 mg, tablets |
Last reviewed date of this leaflet 04/2023.
More detailed information about this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.